Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04733274
Other study ID # 18.081.01
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 22, 2018
Est. completion date July 1, 2024

Study information

Verified date July 2023
Source Boston College
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Technologic advances (i.e. next generation sequencing technologies and novel bioinformatics approaches) have been drivers of scientific discovery and have deepened our understanding of the genetics and genomics of health and disease. In parallel, the falling cost of sequencing has led to screening moving from specialty clinics into the primary care setting. However, our ability to help patients and families understand these technologies and related genetic health literacy issues lag behind. These factors pose a number of questions and challenges for clinicians including: how can we best present complex genetic/genomic information to patients to ensure that patients understand the information and can make informed decisions? What are the specific information and support needs of patients and families to be able to make decisions that are in line with their values? In collaboration with investigators from the Harvard Reproductive Endocrine Sciences Center at the Massachusetts General Hospital, this project broadly aims to examine patient understanding and factors affecting decisions surrounding genetic testing. Using the paradigm of a rare genetic disorder (isolated gonadotropin releasing hormone [GnRH] deficiency - hypogonadotropic hypogonadism/Kallmann syndrome [HH/KS]) we will examine the views and perspectives of patients and healthcare professionals alike regarding genetic/genomic information and testing with the intention of identifying patient-centered responses to these unmet needs and challenges.


Description:

The focus of this study is to better understand perspectives on genetic testing. The study will collect and analyze both quantitative and qualitative data form healthcare professionals as well as patients. Findings will be used to inform more person-centered approaches to genetic testing that will support high-quality decisions that are informed and aligned with patient values and preferences. To achieve this, the study has three specific aims. Aim 1. Evaluate the understandability and acceptability of education materials (including information on genetic testing) co-created with patients. Patient education materials will be created drawing on healthcare professionals expertise (i.e. content experts) and patients (i.e. lived experience). Quality of materials will be quantitatively measured using the gold standard Patient Education Materials Assessment Tool (PEMAT). Aim 2. Identify the central elements for a patient decision aid using expert clinician opinion. Healthcare professionals who are content experts in the field will be surveyed to determine key information for a proposed genetic testing decision aid. Quantitative findings will guide the content of a patient decision aid for genetic testing. Aim 3. Explore patient needs for information and support related to genetic testing. Qualitative focus groups with patients will be conducted and analyzed using thematic analysis. Findings will inform the development of a patient decision aid for genetic testing that is responsive to the aspects which matter most to patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 227
Est. completion date July 1, 2024
Est. primary completion date June 21, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. self-identified as having been diagnosed with either normosmic hypogonadotropic hypogonadism (HH) or Kallmann syndrome (KS) 2. between the ages of 18-70 years 3. primary language is English/capable of responding to a written questionnaire in English 4. has lived in the United states for 5 years or longer 5. checking the opt-in electronic consent Exclusion Criteria: 1. other diagnosis of hypogonadism i.e. Klinefelter syndrome, or adult-onset hypogonadotropic hypogonadism 2. outside the stated age range

Study Design


Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts
United States Boston College Chestnut Hill Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Boston College Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

References & Publications (3)

Dwyer AA, Uveges M, Dockray S, Smith N. Advancing qualitative rare disease research methodology: a comparison of virtual and in-person focus group formats. Orphanet J Rare Dis. 2022 Sep 11;17(1):354. doi: 10.1186/s13023-022-02522-3. — View Citation

Dwyer AA, Uveges MK, Dockray S, Smith N. Exploring Rare Disease Patient Attitudes and Beliefs regarding Genetic Testing: Implications for Person-Centered Care. J Pers Med. 2022 Mar 16;12(3):477. doi: 10.3390/jpm12030477. — View Citation

Dwyer AA, Zeng Z, Lee CS. Validating online approaches for rare disease research using latent class mixture modeling. Orphanet J Rare Dis. 2021 May 10;16(1):209. doi: 10.1186/s13023-021-01827-z. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the understandability and acceptability of education materials (including information on genetic testing) cocreated with patients Patient Education Materials Assessment Tool (PEMAT): higher scores indicate materials that are more readily understood and actionable by patients 1-hour post-test
Primary Identify the central elements for a patient decision aid using expert clinician opinion survey with Likert-type scale questions: higher scores indicate a perceived higher priority for respective items/topic matter baseline
Primary Explore patient needs for information and support related to genetic testing Qualitative focus group findings (thematic analysis) - open ended questions will probe the nature of experiences with genetic testing as well as perceived promoters and barriers to testing and sharing results with potentially at-risk blood relatives baseline
Secondary Compare face-to-face and virtual focus group formats similarities/differences in face-to-face vs. virtual focus groups - emergent themes form face-to-face and virtual focus groups will be compared to identify similarities/differences in the type and quantity of elicited codes baseline
See also
  Status Clinical Trial Phase
Completed NCT01403532 - Sequential Therapy for Hypogonadotropic Hypogonadism Phase 4
Recruiting NCT03687606 - Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH) Phase 4
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Terminated NCT03118479 - Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH) Phase 1
Recruiting NCT01601171 - Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
Completed NCT01438034 - Kisspeptin in the Evaluation of Delayed Puberty Phase 1
Recruiting NCT00914823 - Kisspeptin Administration in the Adult Phase 1
Completed NCT01914172 - Health Needs of Patients With Kallmann Syndrome N/A
Completed NCT00392457 - Investigating the Regulation of Reproductive Hormones in Adult Men N/A
Recruiting NCT05971836 - The Molecular Basis of Inherited Reproductive Disorders
Completed NCT00494169 - Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders
Completed NCT00493961 - Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism Phase 1
Enrolling by invitation NCT00623116 - A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland N/A
Recruiting NCT02880280 - Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Phase 4
Terminated NCT00064987 - Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism Phase 2
Completed NCT00392756 - Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS) Phase 1